PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Cellumed is showing quarter-to-quarter swings between profit and loss amid structural risks including a major shareholder change and delayed payment of a US royalty lawsuit settlement.
In January 2026, a third-party share issuance changed the largest shareholder from Inscobee to the investment partnership TD Landmark Union 1.
Payment of the Buechel-Pappas Trust royalty lawsuit settlement has not proceeded as planned, leaving a risk that the settlement could be voided.
Both operating and net profit turned positive in 2025Q3 and 2026Q2, but the company swung back to losses in the intervening 2025Q4 and 2026Q1.
The company received a disclaimer of opinion on its 2025 half-year audit review, with auditors flagging going-concern uncertainty.
Annual revenue fluctuated after 2022 and rose to KRW 140.19 billion in 2025, but operating losses persisted across all four years.
Cellumed operates three business segments: medical devices, biologics, and cosmeceuticals. The medical device segment covers tissue engineering for demineralized bone matrix (DBM) and synthetic knee cartilage (BMG), as well as artificial knee joints (TKR) and allograft handling.
The biologics segment's key products include the bone morphogenetic protein rhBMP2 and the hyaluronic-acid-based synovial fluid substitute Viscoseal Syringe. The cosmeceutical segment supplies maple-sap-derived functional cosmetics to roughly 2,000 specialty cosmetics distribution channels in China.
However, a substantial portion of consolidated revenue comes from a construction equipment segment run through subsidiaries, with Insgreen and Environment ENG among the key affiliates.
The company produces allograft bone products such as 'Dental Powder,' the bone regeneration device 'Rafugen DBM,' allogeneic skin (ADM) grafts, and the bone morphogenetic protein 'Bio BMP2'; Rafugen DBM, which received US FDA approval in 2018, is described by the company as delivering bone regeneration performance comparable to top-tier global bone grafts based on its high DBM content.
On the ownership front, a KRW 17 billion third-party share issuance in January 2026 reduced Inscobee's stake to 12.1% while the investment partnership TD Landmark Union 1 secured a 33.9% stake to become the new largest shareholder.
Inscobee has reportedly continued to reduce its holdings through on-market sales since then. Competitively, the company operates in the domestic allograft and artificial joint market alongside several local players including L&C BIO.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩35.4B | -₩4.3B | −12.2% |
| 2025Q3 | ₩37.3B | ₩1.4B | 3.9% |
| 2025Q4 | ₩28.3B | -₩600M | −2.3% |
| 2026Q1 | ₩23.4B | -₩1.6B | −6.7% |
| 2026Q2 | ₩30.8B | ₩1.6B | 5.1% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩122.1B | -₩2.7B | -₩5.6B | −2.2% | −10.3% | 69.2% |
| 2023 | ₩95.6B | -₩10.5B | -₩37.3B | −10.9% | −166.1% | 188.8% |
| 2024 | ₩129.1B | -₩6.8B | -₩31.5B | −5.3% | −359.4% | 675.0% |
| 2025 | ₩140.2B | -₩5.1B | -₩2.2B | −3.7% | −26.7% | 625.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue fell from KRW 122.09 billion in 2022 to KRW 95.55 billion in 2023, before rising again to KRW 129.14 billion in 2024 and KRW 140.19 billion in 2025.
Operating losses widened from KRW 2.73 billion in 2022 to KRW 10.46 billion in 2023, then gradually narrowed to KRW 6.83 billion in 2024 and KRW 5.13 billion in 2025.
Net loss attributable to owners expanded sharply from KRW 5.57 billion in 2022 to KRW 37.30 billion in 2023 and KRW 31.55 billion in 2024, before narrowing markedly to KRW 2.24 billion in 2025, a change that appears to reflect one-off factors such as the reversal of litigation-related provisions.
On a quarterly basis, revenue of KRW 35.37 billion in 2025Q2 came with an operating loss of KRW 4.31 billion and a net loss of KRW 2.53 billion, before the company swung to an operating profit of KRW 1.45 billion and a net profit of KRW 7.96 billion on revenue of KRW 37.29 billion in 2025Q3.
Revenue then dropped to KRW 28.28 billion in 2025Q4, with an operating loss of KRW 0.65 billion and a net loss of KRW 6.20 billion, before 2026Q1 posted revenue of KRW 23.42 billion, an operating loss of KRW 1.58 billion, and a net loss of KRW 1.68 billion.
In 2026Q2, revenue recovered to KRW 30.81 billion with an operating profit of KRW 1.56 billion and a net profit of KRW 2.60 billion, marking another swing back into profitability.
This alternating pattern across the last five quarters reflects both underlying revenue volatility and the outsized influence of one-off items such as litigation provision reversals on quarterly net income.
The debt ratio climbed sharply from 69.2% in 2022 to 188.8% in 2023, 675.0% in 2024, and 625.9% in 2025, underscoring persistent balance-sheet fragility.
The domestic allograft bone and skin graft market has continued to see moderate growth on the back of rising orthopedic and reconstructive surgery demand tied to an aging population and advancing transplantation techniques, with allografts favored industry-wide for their low infection risk and strong adhesion capability.
However, since domestic tissue donation alone cannot meet demand, reliance on imported human tissue has grown, with data from the Ministry of Food and Drug Safety showing imported tissue accounting for the large majority of total supply volume in past reporting.
This makes raw material supply stability a key variable differentiating production capacity and results across companies, and Cellumed itself previously experienced raw material supply instability before signing agreements to diversify its overseas supply chain.
Competitively, the company contends with other listed domestic players in the same industry, with its rhBMP2-based bone morphogenetic protein products and its US FDA-approved DBM product portfolio cited as technical differentiators.
That said, recurring non-operating issues at Cellumed—including financial-structure instability, governance changes, and litigation risk—have kept market skepticism alive about the company's execution relative to underlying industry growth.
The fact that a construction equipment segment accounts for a substantial share of revenue also complicates straightforward valuation comparisons with pure biologics or medical device peers.
When announcing the change in largest shareholder in January 2026, the company stated it would reorganize and build a profitability-focused management system, positioning 2026 as the founding year of an earnings turnaround while focusing on enhancing shareholder value and restoring market trust.
The plan called for proceeds from the share issuance to be applied first to litigation-related debt repayment, with the remainder used as working capital. In practice, however, portions of the settlement payments scheduled for January and February were not paid on time, confirming a gap between plan and execution.
On the operating side, the company announced a partnership with an overseas raw material supplier in May 2025 to strengthen stable production for bone formation and skin graft products, stating that expanded production capacity following process improvements, combined with a reinforced supply chain, would support its competitive position.
The company has also continued sales network activities such as showcasing its Rafugen DBM and artificial joint lineup at orthopedic association events.
Nonetheless, full settlement of the litigation payment, stabilization of the controlling shareholder structure, and resolution of audit-opinion-related uncertainty remain the key variables that will determine the credibility of any earnings outlook going forward.
The current share price trades at a premium to the company's net asset value, and share price volatility has historically spiked sharply whenever governance-change issues surfaced.
On an earnings basis, profitability has alternated between gains and losses over the last four quarters without a stable trend, making conventional earnings-based valuation metrics difficult to apply meaningfully.
The company appears not to have paid dividends in recent years, consistent with its history of sustained losses and capital impairment.
Net asset levels themselves have swung considerably since 2022 due to repeated litigation-related loss recognition and capital raises, so changes driven by individual events warrant as much attention as simple peer comparisons.
Overall, valuation currently appears to be driven more by litigation and governance events than by underlying business fundamentals.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
In January 2026, a new largest shareholder, TD Landmark Union 1, secured equity through a third-party allotment capital increase of KRW 17 billion, bringing in fresh funds. The company stated that the raised funds would be prioritized for repaying debts related to litigation.
This capital infusion is assessed as a factor that could help ease the burden of capital impairment in the short term.
In Q3 2025 and Q2 2026, both operating profit and net income turned positive, demonstrating that profitability can improve when revenue expansion and cost control occur simultaneously. The company also explained that it expects improved performance in the second half once raw material supply issues are resolved.
Should revenue remain stable going forward and the impact of one-off factors diminish, there is a possibility that such profitable quarters could recur.
The company holds technically differentiated assets, including a large-scale expression system for the bone morphogenetic protein rhBMP2 and Rapugen DBM, which has received US FDA approval.
Allograft bone and allograft skin implant materials are considered highly preferred products in the industry due to their low infection risk and excellent adhesion capability. The cosmeceutical division also functions as a separate revenue source, having already secured distribution channels in China.
There have been repeated cases where part of the settlement amount agreed with the US Vitrimax Papas trust administrator was not paid by the scheduled deadline.
Under the terms, failure to fulfill the payment obligation would result in termination of the settlement and require repayment of the full judgment amount plus additional legal costs, raising the possibility of renewed financial burden.
It is reportedly the case that the company is exploring renegotiation through a law firm, but the final outcome has not yet been confirmed.
The largest shareholder has changed multiple times over a period of just over a year, and suspicions have been raised regarding execution practices, such as funds raised through capital increases being lent to affiliated entities for purposes other than originally stated.
This has become a backdrop for mentions of possible investigation into false disclosure under the Capital Markets Act. Such instability in corporate governance could act as a burden on the recovery of investor trust.
In the 2025 semi-annual audit, both the consolidated and separate financial statements received a 'disclaimer of opinion,' with the audit pointing out significant uncertainty regarding the company's ability to continue as a going concern.
There was a period when the capital impairment ratio exceeded the criteria for designation as an administrative issue, and the debt ratio has also remained at a very high level in recent years.
Such financial vulnerability is a factor that could directly affect stock price and trading depending on future additional capital raising or changes in audit opinion.
The company finally lost a 12-year royalty lawsuit with the US's Vitrimax Papas, receiving a judgment for approximately KRW 24 billion in damages, and although the settlement amount was subsequently reduced through agreement, payment delays have recurred.
If the settlement is ultimately voided, the terms require repayment of the full judgment amount plus additional legal costs, posing a significant potential financial shock. The final resolution of this lawsuit is a key variable that will continue to affect future performance and financial structure.
Due to a history of capital impairment, a high debt ratio, and limited cash-equivalent assets, liquidity capacity remains constrained. A significant portion of loans extended to affiliated entities carries recovery uncertainty, raising the possibility of further capital erosion if reflected as bad debt.
Should additional capital raising be needed in the future, the burden of equity dilution on existing shareholders could also increase.
Concerns have been raised about delayed decision-making as the largest shareholder changed multiple times within a short period and the union's capital contribution structure was repeatedly restructured.
Questions have also been raised about the reliability of disclosures, including inconsistencies between the stated purpose and actual execution of funds from the capital increase, as well as a history of designation as an unfaithful disclosure company.
Such governance uncertainty could directly affect future audit opinions and whether the company is designated as an administrative issue stock.
The 2026Q3 report is due around this time; it will show whether the profit-turn pattern seen in 2025Q3 and 2026Q2 repeats or whether the company reverts to loss.
Additional disclosures on whether the remaining Buechel-Pappas Trust settlement payment has been completed and whether the settlement remains in force should be monitored.
The FY2026 annual audit report's opinion should be checked to see whether going-concern uncertainty has been resolved.
Continued monitoring is needed for any further changes in the ownership structure of largest shareholder TD Landmark Union 1, including changes in its investor composition or additional stake sales/purchases.
Cellumed holds technical assets such as its bone morphogenetic protein platform and FDA-approved DBM product line, but its recent years of results have not escaped a structure combining revenue growth with persistent operating losses.
The swings into profit in 2025Q3 and 2026Q2 are a positive signal, though a substantial part appears attributable to one-off factors such as litigation provision reversals, and the sustainability of this pattern has not yet been confirmed.
The January 2026 change in largest shareholder and the accompanying capital raise eased near-term liquidity pressure, but the subsequent failure to make settlement payments as planned has brought the risk of a voided settlement back into focus.
Layered on top of this are non-operating risks including repeated governance changes, uncertainty over recovery of loans to related parties, and a history of disclaimed audit opinions, meaning signs of earnings improvement coexist with substantial financial and governance uncertainty.
Before drawing any conclusions, it is worth tracking the persistence of quarterly results, whether the litigation settlement is actually honored, and the trend in audit opinions.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.